Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Zhongshan Ophthalmic Center, part of Sun Yat-Sen University, is a Chinese company located in Guangzhou that operates hospitals.

GNT Pharma Co., Ltd. is a holding company, which develops new drugs for neurological and inflammatory diseases. Its pipeline include Neu2000, AAD-2004, and AAD-2004OAc. The company was founded by Byoung Joo Gwag, Seung Up Kim, Cheol Kim, Jai Sung Noh, Eui Ju Choi, Young Joon Oh, Cheon Gi Joo, and Sung Hwa Yoon on April 3, 1998 and is headquartered in Osan, South Korea.

Baiyuete Biotechnology (Shanghai) Co., Ltd., established on 2012-05-22, Business scope includes food production,import and export of food,wholesale,commission agent(except auction),and provide related services,technical consulting,Technical service and self-owned technology transfer,Wholesale of prepackaged food(Does not contain refrigerated frozen food),General cargo warehousing business(except dangerous goods),Biological Technology(genetically modified organism,human stem cells,Except genetic diagnosis and treatment)Technology research and development in the field,Technical Support,technology transfer. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Precision Vision (Beijing) Medical Technology Co., Ltd., established on 2018-04-16, Business scope includes technology development,Technical Services,technology transfer,Technology Promotion,technical consulting;Sales Ι,Class II medical device.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Matsushita Electronics Corp. develops and manufactures electronic products. Its products include plasma TVs, DVD players, and digital cameras. It is a subsidiary of Matsushita Electric Industrial Co. Ltd. The company is headquartered in Osaka, Japan.

MingMed is a Chinese company with global competitiveness in independent drug research and development. The company's main product pipeline includes, among other things, ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs, and pet immune drugs, as well as a number of potential First-in-Class innovative drugs that have reached the clinical stage.

Molecular Targeting Technologies, Inc. is an American private company located in West Chester, PA, that operates as a biotechnology company. It was founded in 1993. Chris Pak is the CEO, in this role since 2001.\nThe company says this about itself: Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022.

Shenyang Eye Industry Technology Research Institute Co., Ltd., established on 2017-09-01, Business scope includes research and development of ophthalmic drugs;chemical preparation,Chinese patent medicine research and development;IIIkind6804Ophthalmic Surgical Instruments,IIIkind6822Medical Optics,Instruments and endoscopic equipment,IIIkind6846Implantable materials and artificial organs,IIkind6864Research and development of medical hygiene materials and dressings;Bioengineering technical support,technical consulting,Technical Services,Technical Training,technology transfer,Technology Promotion;public laboratory rental;Research and development of optical electromechanical testing equipment;Research and development of opto-electromechanical screening diagnosis and treatment equipment;plant,Technology research and development of microbial natural active substances,Technical Services,technology transfer;Healthy food,Cosmetic technology development,Technical Services,technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Wenzhou Eye Optometry Development Co., Ltd., established on 2013-01-05, Business scope includes hospital investment management;Business Management Consulting;Industrial Investment,Own Equipment Rental(Excluding financial leases),asset Management;Glasses frame,Development of lenses and low vision aids,Sales,technical consulting;Optometry professional consultation;Medical Technology Consulting;Medical Information Consultation(The above does not include medical services);Science and Technology Information Consulting;Glasses processing and repair;R&D of software technology,test,Consulting Services and Technology Transfer;care solution,other daily necessities,cosmetic,Sales of health products;clothing,furniture,lamps,Office Supplies,Wujinjiaodian,household appliances,Research and development of electronic products,Sales,technical consulting;Medical device management(see specific project<Medical device operating enterprise license>,Operating within the validity period of the above license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Torrent Pharma, with annual revenues of more than Rs 8,000 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 20,500 crores. It is ranked 8th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), and Vitamins Minerals Nutritionals (VMN). Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 700 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with the 90 year old Heumann from Pfizer to enter the German market. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Today, the Company has presence in more than 40 countries and is ranked No. 1 among the Indian pharma Companies in Brazil, Germany, and the Philippines.

Having "Ever Researching for a Brighter World" as our motto, Nichia has grown in the field of manufacturing and sales of fine chemicals, particularly inorganic luminescent materials (phosphors). In the process of the challenging pursuit of brighter luminescent and light-emitting materials, we succeeded in developing and commercializing the super high brightness Blue LED in 1993. It was accepted with great amazement in the related industries throughout the world. Since the first announcement of the Blue LED in 1993, Nitride-based LEDs in different emission colors ranging from Ultraviolet to Yellow have been contributing to the diversification of LED application fields. In addition to LEDs, a lot of resources are now being focused on the R/D of bluish purple laser diodes, which will definitely play a key role for the further expansion of the information media industry. We have a belief that Nitride-based semiconductors will become one of the most exciting areas of the semiconductor industry in the near future.We hope that Nichia will continue to be a company that will be able to make a contribution to the world by evolving its original and unique technologies in the field of manufacturing.

4D Pharma Research Ltd., a subsidiary of 4D Pharma Plc, is a company headquartered in Aberdeen, UK, that engages in research and experimental development on biotechnology.